News | Pharmaceuticals | February 01, 2018

Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

The National Aeronautics and Space Administration (NASA) awarded a grant to evaluate Humanetics Corporation's investigational new drug, BIO 300

 

Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the National Aeronautics and Space Administration (NASA) and the National Space Biomedical Research Institute (NSBRI), which evaluated the potential of Humanetics’ investigational drug, BIO 300, to mitigate the toxicities from space-like radiation exposure.

The research tested BIO 300’s ability to protect both animal and human cells from space-like radiation exposure (e.g. protons and mixed-fields). One focus of these projects: evaluating BIO 300’s ability to protect the cardiovascular system. This is of special interest to NASA due to concern for radiation-induced cardiovascular disease. Protection against space radiation is required for long-duration missions in space, including a manned-trip to Mars.

StemoniX partnered with Humanetics for the research. StemoniX is a Minnesota company with a microHeart Assay Ready platform containing functional human heart tissue derived from induced pluripotent stem cells (iPSCs). These heart cells are organized in screening plates simulating tissue architecture and “beat” rhythmically in culture, reproducing human cardiovascular biology. BIO 300 protected the microHeart cells from various doses of the mixed-field radiation, enhancing their survival following mission-relevant doses of radiation. Cardiac radioprotection was also demonstrated in a separate study using proton radiation.

The data were recently presented at the NASA Human Research Program conference in Galveston, Texas by Michael Kaytor, vice president of research and development at Humanetics. “The response from NASA has been positive and encouraging,” said Kaytor. “Our ultimate goal is to make BIO 300 available for astronauts, enabling exploration deeper into the solar system.”

BIO 300 is also being developed for other uses, including in cancer radiation treatment to protect normal tissues from harm and for military use to protect warfighters in areas of nuclear or radiological concern. BIO 300 is currently being evaluated in a multi-site clinical trial involving patients receiving radiation and chemotherapy for non-small cell lung cancer.

For more information: www.humaneticscorp.com

Related Content

Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all
Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018
Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life...
Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
Overlay Init